Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

Gynecological Endocrinology

Volumn 22, Issue 4, 2006, Pages 179-184

  García Pérez, Miguel ^a   Moreno Mercer, Jane ^a   Tarín, Juan ^a   Cano, Antonio ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bone markers; Bone mass; Estradiol; Low dose hormone therapy; Menopause; N telopeptides; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTRADIOL; PROGEFFIK; PROGESTERONE;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; NORMAL HUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE;

ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; POSTMENOPAUSE;

EID: 33745727242     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590600624291     Document Type: Article

References (27)

1. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999;6: 273-276.
2. Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric 2001;4:110-119.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288: 321-333.
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-1712.
5. North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003;10:6-12.
6. Lobo RA, Ettinger B, Hutchinson KA, Knopp RH, Lindsay R, Nachtigall LE, Santoro N, Studd J. Estrogen replacement. The evolving role of transdermal delivery. J Reprod Med 1996;41:781-796.
7. Montgomery RV. Hormone replacement therapy: optimising the dose and route of administration. Drugs Aging 2002;19:807-818.
8. Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 2000;6:419-426.
9. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004;4:50-63.
10. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005;27:1-11.
11. Garcia-Perez MA, Moreno-Mercer J, Tarin JJ, Cano A. Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women. Maturitas 2003;45:67-74.
12. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-1536.
13. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000;11:76-82.
14. Garnero P, Bianchi F, Carlier MC, Genty V, Jacob N, Kamel S, Kindermans C, Plouvier E, Pressac M, Souberbielle JC. [Biochemical markers of bone remodeling: pre-analytical variations and guidelines for their use. SFBC (Societe Francaise de Biologie Clinique) Work Group. Biochemical markers of bone remodeling]. Ann Biol Clin (Paris) 2000;58:683-704.
15. Woitge HW, Scheidt-Nave C, Kissling C, Leidig-Bruckner G, Meyer K, Grauer A, Scharla SH, Ziegler R, Seibel MJ. Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab 1998;83:68-75.
16. Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-14.
17. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ III, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172-178.
18. 2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003;10:241-249.
19. Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP, Delmas PD. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int 1999;9:358-366.
20. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999;94:330-336.
21. Lindsay R, Hart DM, Purdie D, Ferguson MM, Clark AS, Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978;54:193-195.
22. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-490.
23. Utian WH, Burry KA, Archer DF, Gallagher JC, Boyett RL, Guy MP, Tachon GJ, Chadha-Boreham HK, Bouvet AA. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181:71-79.
24. Minisola S, Pacitti MT, Ombricolo E, Costa G, Scarda A, Palombo E, Rosso R. Bone turnover and its relationship with bone mineral density in pre- and postmenopausal women with or without fractures. Maturitas 1998;29:265-270.
25. Weaver CM, Peacock M, Martin BR, McCabe GP, Zhao J, Smith DL, Wastney ME. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J Bone Miner Res 1997;12:1714-1720.
26. Takahashi M, Kushida K, Hoshino H, Miura M, Ohishi T, Inoue T. Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis. Clin Endocrinol (Oxf) 1997;47:177-183.
27. Bjarnason NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000;26:561-569.